Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA clears initiation of phase I study of DT-2216 for solid tumors

March 4, 2021

FDA clears IND for pilot study of NVD-003 for congenital pseudarthrosis of the tibia

March 4, 2021

MiR-939-5p, tumor suppressor and potential therapeutic target in TNBC

March 4, 2021

Benralizumab achieves OCS elimination or reduction in OCS-dependent asthmatics

March 4, 2021

PHA-022121 shows promise for treating hereditary angioedema

March 4, 2021

Positive topline data from phase II program of AZR-MD-001 in Meibomian gland dysfunction

March 4, 2021

Galapagos reports interim data from safety studies of filgotinib

March 4, 2021

Wellmarker Bio receives phase I study approval for WM-S1-030 in Australia

March 4, 2021

Arbutus Biopharma identifies HBsAg secretion inhibitors

March 4, 2021

Xentria submits IND application to the FDA for XTMAB-16 as treatment of sarcoidosis

March 4, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026